Indication: Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of ≥30 kg/m² (obese), or • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, or dyslipidaemia and who have failed a previous weight management intervention. Treatment with Saxenda® should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.
Contraindication: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the full Israeli PI Special warnings: Saxenda® must not be used as a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients after rapid discontinuation or dose reduction of insulin (see section 4.2 of the full Israeli PI) Cholelithiasis and cholecystitis In clinical trials for weight management, a higher rate of cholelithiasis and cholecystitis was observed in patients treated with liraglutide than in patients on placebo Dehydration Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with GLP-1 receptor agonists. Patients treated with liraglutide should be advised to avoid fluid depletion. Safety profile: The most frequently reported adverse reactions during treatment with Saxenda® were: nausea, vomiting, diarrhoea and constipation. For further information please refer to the full PI as appears in the MOH website.

1.Physician Leaflet approved by MOH Saxenda Nov 2020.